Genomic test could personalize prostate cancer treatment

A new genomic test could help doctors personalize prostate cancer treatment by identifying which high-risk patients truly benefit from intensive therapy, according to findings presented at a major cancer conference in Madrid. Researchers from University College London analyzed data from 27,607 real-world patients and 401 men in the STAMPEDE trial, finding that higher Decipher scores consistently predicted worse outcomes, including increased risk of metastasis and death from prostate cancer. The test could spare men with low scores from aggressive treatment side effects like fatigue, while prioritizing intensive therapy for those with high scores, though further validation is needed before routine clinical use.